Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 18/20 | 0.54 |
| ▸ | FPR3 | P25089 | 1/20 | 0.54 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.54 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2793497 | 0.92 | CCR1 (0.49) | CCR1FPR3GPR65GPR35KCNH2 | |
| SCHEMBL2794695 | 0.88 | CCR1 (0.51) | CCR1FPR3GPR65GPR35KCNH2 | |
| SCHEMBL2799145 | 0.85 | CCR1 (0.50) | CCR1FPR3GPR65GPR35KCNH2 | |
| SCHEMBL2795770 | 0.85 | CCR1 (0.49) | CCR1FPR3GPR65GPR35KCNH2 | |
| SCHEMBL2793004 | 0.80 | CCR1 (0.46) | CCR1FPR3GPR65GPR35KCNH2 | |
| SCHEMBL2797155 | 0.80 | PTGDR2 (0.45) | CCR1FPR3GPR65GPR35 | |
| SCHEMBL2798190 | 0.78 | CCR1 (0.48) | CCR1FPR3GPR65GPR35KCNH2 | |
| SCHEMBL2795728 | 0.78 | CCR1 (0.47) | CCR1FPR3GPR65GPR35KCNH2 | |
| SCHEMBL4634369 | 0.76 | CCR1 (0.62) | CCR1FPR3GPR65GPR35 | |
| SCHEMBL4634497 | 0.74 | CCR1 (0.59) | CCR1FPR3GPR65GPR35MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010077915-A1 | NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-07-08 | — | — | WO | claimed |
| US-20100168080-A1 | NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-07-01 | — | — | US | claimed |
| WO-2010077915-A1 | NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-07-08 | — | — | WO | disclosed |
| US-20100168080-A1 | NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168080-A1 | NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | CCR1, CCR5, CCR3 | CCR1 1/4885FPR3 56/4885GPR65 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.